Foundation Care LLC

Foundation Care LLC, a specialty pharmacy subsidiary of Centene Corporation based in Chesterfield, Missouri, supplies oncology and hematology medications to federal healthcare facilities as a prime contractor operating exclusively in the full-and-open market with no set-aside designations. The company is a for-profit limited liability company competing across 124 recent federal awards with a combined potential value of $2.1 million, all obligated, across the Department of Veterans Affairs and Department of Justice correctional healthcare systems.

Foundation Care's capability footprint centers on ponatinib-based chemotherapy medications, particularly Iclusig formulations (15mg, 30mg, 45mg tablet strengths) used to treat chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, supplied through firm fixed-price purchase orders to VA medical centers and federal correctional facilities. The company's NAICS profile reflects this specialization: 64 of 124 awards sit under Pharmaceutical Preparation Manufacturing (NAICS 325412), with an additional 27 awards under Surgical Appliance and Supplies Manufacturing and 15 under Pharmacies and Drug Stores. PSC coding tracks similarly, with 87 awards classified under Drugs And Biologicals (PSC 6505) and 36 under Medical And Surgical Instruments, Equipment, And Supplies. Representative awards include a $51.1 million purchase order from Federal Medical Center Lexington (October 2024 through March 2025) for chemotherapy medications, a $83.7 thousand order from Veterans Integrated Service Network 6 for Iclusig 15mg tablets (March 2024), and monthly recurring purchase orders from Federal Medical Center Rochester for Foundation Care branded crenessity medication at approximately $14.4 thousand per order (July 2026).

Customer concentration is acute and divided by agency. The top five customers by award count and potential value account for 64% and 82% of all awards, respectively, with Veterans Integrated Service Network 21 (24 awards, $641 thousand combined potential value) and the Department of Justice Bureau of Prisons Federal Medical Center Lexington (19 awards, $562 thousand) anchoring the portfolio. The VA's network-based structure fragments purchases across multiple VISNs — VISN 21, VISN 6, VISN 10, and VISN 9 collectively represent the largest concentration — while DOJ's two federal correctional complexes (Lexington and Terre Haute) represent the second-largest customer bloc. Foundation Care holds no parent contract vehicles, GWACs, BPAs, or IDIQs; all 124 awards are direct purchase orders issued individually by ordering officers at VA medical centers and federal correctional healthcare facilities.

Activity peaked in 2021 with 18 awards before declining to four awards in 2024, then rebounding to seven awards through mid-2026. The decline from 2021 to 2023–2024 followed by partial recovery reflects purchasing cyclicality in federal medical supply procurement rather than loss of customer relationships, as recent awards from Federal Medical Center Rochester (July 2026) and Veterans Integrated Service Network 2 (February–March 2026) demonstrate active ongoing engagement. Foundation Care operates exclusively as a prime contractor (100% of awards); the company subcontracts to no other federal vendors and receives no subcontract awards itself. Place of performance for recent orders centers on Sand Lake, Florida and Wildwood, Missouri, consistent with Centene's specialty pharmacy distribution footprint.